The present disclosure provides a preparation method of dihydroquercetin, belonging to the field of synthesis of drugs. The method includes steps of: adjusting reaction solvent water to be alkaline with an alkalizing reagent, to obtain an alkaline aqueous solution; dissolving quercetin dihydrate in the alkaline aqueous solution, and adding a sulfite binary combined reducing agent to carry out reduction reaction, to obtain an endpoint reduction reaction solution; diluting the endpoint reduction reaction solution with water, and then acidizing, aging, and filtering the resultant to obtain a filtrate and a filter cake; subjecting the filtrate to extraction, washing, drying, and vacuum concentration to obtain a concentrated crude product; and repeatedly crystallizing the concentrated crude product to obtain dihydroquercetin. The preparation method of the present disclosure has readily available raw materials, a simple process, and low production costs, and is particularly suitable for industrial production.
The present disclosure provides a semi-synthetic method of dihydroquercetin, belonging to the field of synthesis of organic drugs. The semi-synthetic method includes the following steps: adding quercetin dihydrate to solvent water adjusted to be alkaline with an alkalizing reagent, heating and stirring to dissolve the mixture, and then adding thiourea dioxide under the protection of an inert gas to perform a reduction reaction, to obtain an endpoint reduction reaction solution; diluting the endpoint reduction reaction solution with water and cooling the resultant, and then acidizing, aging, and filtering the resultant to obtain a filtrate and a filter cake; extracting, washing, drying, concentrating, and repeatedly crystallizing the filtrate to obtain dihydroquercetin; and recycling the filter cake after being washed.
Provided in the present disclosure is a method for preparing dihydroquercetin, which belongs to the field of pharmaceutical synthesis. The method comprises the following steps: adjusting reaction solvent water to be alkaline with an alkalizing reagent to obtain an alkaline aqueous solution; dissolving quercetin dihydrate in the alkaline aqueous solution, and adding a sulfite reducing agent for binary combination to perform a reduction reaction in order to obtain an end reduction reaction solution; diluting the end reduction reaction solution with water, and then acidifying, aging and filtering the diluted solution to obtain a filtrate and a filter cake; extracting, washing, drying and concentrating the filtrate in a vacuum to obtain a concentrated crude product; and recrystallizing the concentrated crude product to obtain the dihydroquercetin. The preparation method of the present disclosure has the advantages of readily available raw materials, a simple process and a low production cost, and is especially suitable for industrial production.
The present disclosure provides a semi-synthetic method for dihydroquercetin, which belongs to the field of organic and pharmaceutical synthesis. The semi-synthetic method comprises the following steps: adjusting solvent water to be alkaline by using an alkalizing agent, then adding dihydroquercetin therein, heating and stirring to dissolve, then adding thiourea dioxide under the protection of an inert gas to carry out a reduction reaction to obtain an end point reduction reaction solution; diluting the end point reduction reaction solution by using water and then cooling, then acidifying, aging and filtering to obtain a filtrate and a filter cake; extracting the filtrate, then washing, drying, concentrating and recrystallizing to obtain dihydroquercetin, and recovering and reusing the filter cake after washing. The raw materials and reagents used in the semi-synthetic method of the present disclosure are cheap and easy to obtain, the process is simple, production costs are low, and the method is especially suitable for industrial production.
The present invention relates to an epitope on fibronectin B (ED-B) domain, more specifically to an antibody or an antibody fragment of ED-B domain, and can be widely applied in in-vitro detection and in-vivo positioning of ED-B domain as well as in targeted cancer therapy.
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
The present invention relates to an epitope on fibronectin B (ED-B) domain, more specifically to an antibody or an antibody fragment of ED-B domain, and can be widely applied in in-vitro detection and in-vivo positioning of ED-B domain as well as in targeted cancer therapy.
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
A61K 39/00 - Medicinal preparations containing antigens or antibodies
7.
Human antibody against ED-B domain of fibronectin and uses thereof
The present invention provides an antibody or antibody fragment for specifically recognizing and binding to an ED-B domain of fibronectin. The antibody or antibody fragment can be widely used for in vitro detection and in vivo location of the ED-B protein domain, as well as targeted therapy of tumors.
The present invention relates to an epitope on a fibronectin B (ED-B) domain, more specifically to an antibody or an antibody fragment of an ED-B domain, and can be widely applied in in-vitro detection and in-vivo positioning of ED-B domains as well as in targeted cancer therapy.
Provided is a drug system design method, comprising selecting a target portion specifically binding a target of interest, and connecting the target portion to a biologically active portion and/or connecting the target portion to a biologically inert portion. Also provided are a test kit, a drug kit or a pharmaceutical composition including a biologically inert drug comprising the target portion and the biologically inert portion and a biologically active drug comprising the target portion and the biologically active portion, wherein the biologically inert drug and the biologically active drug target a same target. Also provided is a method for using the drugs or the pharmaceutical composition to treat diseases such as those related to ED-B.
Disclosed are a use of an ED-B protein as a tissue hyperplasia (such as a tumour) marker, a method for detecting the ED-B protein, and a diagnostic kit comprising the ED-B protein. The kit of the present invention comprises a genetically-engineered antibody against the tumour marker ED-B.
The present invention provides antibody or antibody fragment specifically recognizing and binding to the ED-B domain of fibronectin. Said antibody or antibody fragment can be used for in vitro detection and in vivo localization of ED-B domain, and also can be used for tumor targeted therapy.
patents
